Ausgabe 4/2014
Inhalt (24 Artikel)
The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer
Suqin He, Donald L. Smith, Manuel Sequeira, Jim Sang, Richard C. Bates, David A. Proia
Evaluation of two 125I-radiolabeled acridine derivatives for Auger-electron radionuclide therapy of melanoma
Maryline Gardette, Claire Viallard, Salomé Paillas, Jean-Luc Guerquin-Kern, Janine Papon, Nicole Moins, Pierre Labarre, Nicolas Desbois, Pascal Wong-Wah-Chung, Sabine Palle, Ting-Di Wu, Jean-Pierre Pouget, Elisabeth Miot-Noirault, Jean-Michel Chezal, Francoise Degoul
Small-molecule inhibition of oncogenic eukaryotic protein translation in mesothelioma cells
Esther Z. Chen, Blake A. Jacobson, Manish R. Patel, Aniekan M. Okon, Shui Li, Kerry Xiong, Abhishek J. Vaidya, Peter B. Bitterman, Carston R. Wagner, Robert A. Kratzke
Oxidative cytotoxic agent withaferin A resensitizes temozolomide-resistant glioblastomas via MGMT depletion and induces apoptosis through Akt/mTOR pathway inhibitory modulation
Patrick T. Grogan, Jann N. Sarkaria, Barbara N. Timmermann, Mark S. Cohen
The ability of molecular docking to unravel the controversy and challenges related to P-glycoprotein—a well-known, yet poorly understood drug transporter
Maen Zeino, Mohamed E. M. Saeed, Onat Kadioglu, Thomas Efferth
The combination of RAF265, SB590885, ZSTK474 on thyroid cancer cell lines deeply impact on proliferation and MAPK and PI3K/Akt signaling pathways
Susi Barollo, Loris Bertazza, Enke Baldini, Salvatore Ulisse, Elisabetta Cavedon, Marco Boscaro, Raffaele Pezzani, Caterina Mian
An assessment of the pharmacokinetics, pharmacodynamics, and tolerability of GCPGC, a novel pegylated granulocyte colony-stimulating factor (G-CSF), in healthy subjects
Kwang-Hee Shin, Kyoung Soo Lim, Howard Lee, In-Jin Jang, Kyung-Sang Yu
Phase I study of carboplatin in combination with PM00104 (Zalypsis®) in patients with advanced solid tumors
Ramón Salazar, Antonio Calles, Marta Gil, Ignacio Durán, Margarita García, Manuel Hidalgo, Cinthya Coronado, Vicente Alfaro, Mariano Siguero, Carlos Fernández-Teruel, Raquel Prados, Emiliano Calvo
A phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid tumors
Colin D. Weekes, Muralidhar Beeram, Anthony W. Tolcher, Kyriakos P. Papadopoulos, Lia Gore, Priti Hegde, Yan Xin, Ron Yu, L. Mason Shih, Hong Xiang, Rainer K. Brachmann, Amita Patnaik
Differences in maximum tolerated doses and approval doses of molecularly targeted oncology drug between Japan and Western countries
Hideki Maeda, Tatsuo Kurokawa
Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors
Jordi Rodon, Irene Braña, Lillian L Siu, Maja J De Jonge, Natasha Homji, David Mills, Emmanuelle Di Tomaso, Celine Sarr, Lucia Trandafir, Cristian Massacesi, Ferry Eskens, Johanna C Bendell
Phase 1/2 study of KRN330, a fully human anti-A33 monoclonal antibody, plus irinotecan as second-line treatment for patients with metastatic colorectal cancer
Johanna C. Bendell, Heinz-Josef Lenz, Theresa Ryan, Bassel F. El-Rayes, John L. Marshall, Manuel R. Modiano, Lowell L. Hart, Clint D. Kingsley, Thomas J. George, Daisuke Nakashima, Jordan D. Berlin
Phase I and pharmacokinetic study of trabectedin, a DNA minor groove binder, administered as a 24-h continuous infusion in Japanese patients with soft tissue sarcoma
Takafumi Ueda, Shigeki Kakunaga, Masashi Ando, Kan Yonemori, Hideshi Sugiura, Kenji Yamada, Akira Kawai
Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors
Fatima Rangwala, Johanna C. Bendell, Mark F. Kozloff, Christy C. Arrowood, Andrew Dellinger, Jennifer Meadows, Sandra Tourt-Uhlig, Jennifer Murphy, Kellen L. Meadows, Aijing Starr, Samuel Broderick, John C. Brady, Stephanie M. Cushman, Michael A. Morse, Hope E. Uronis, S. David Hsu, S. Yousuf Zafar, James Wallace, Alexander N. Starodub, John H. Strickler, Herbert Pang, Andrew B. Nixon, Herbert I. Hurwitz
Phase I trial of everolimus, gemcitabine and cisplatin in patients with solid tumors
Brian A. Costello, Mitesh J. Borad, Yingwei Qi, George P. Kim, Donald W. Northfelt, Charles Erlichman, Steven R. Alberts
Evaluation of a novel blood pressure scoring method and its association with clinical response in cancer patients treated with anti-vascular endothelial growth factor therapy
Mehmet Asim Bilen, Jean-Bernard Durand, Lacey McQuinn, Kenneth R. Hess, Siqing Fu, Gerald S. Falchook, David S. Hong, Jennifer J. Wheler, Rabih Said, Michael S. Ewer, Razelle Kurzrock, Aung Naing
A phase I/II study of S-1 with sorafenib in patients with advanced hepatocellular carcinoma
Yoshihiko Ooka, Tetsuhiro Chiba, Sadahisa Ogasawara, Kuniaki Arai, Eiichiro Suzuki, Akinobu Tawada, Tatsuya Yamashita, Fumihiko Kanai, Shuichi Kaneko, Osamu Yokosuka
Randomized phase II trial of sorafenib alone or in combination with carboplatin/paclitaxel in women with recurrent platinum sensitive epithelial ovarian, peritoneal, or fallopian tube cancer
Anita Schwandt, Vivian E. von Gruenigen, Robert M. Wenham, Heidi Frasure, Susan Eaton, Nancy Fusco, Pingfu Fu, John J. Wright, Afshin Dowlati, Steven Waggoner
A phase II study of the gamma secretase inhibitor RO4929097 in patients with previously treated metastatic pancreatic adenocarcinoma
Ana De Jesus-Acosta, Daniel Laheru, Anirban Maitra, John Arcaroli, Michelle A. Rudek, Arvind Dasari, Patrick J. Blatchford, Kevin Quackenbush, Wells Messersmith
A randomized phase II efficacy and safety study of vandetanib (ZD6474) in combination with bicalutamide versus bicalutamide alone in patients with chemotherapy naïve castration-resistant prostate cancer
Arun A. Azad, Emma K. Beardsley, Sebastian J. Hotte, Susan L. Ellard, Lawrence Klotz, Joseph Chin, Christian Kollmannsberger, Som D. Mukherjee, Kim N. Chi
Combination of docetaxel and TSU-68, an oral antiangiogenic agent, in patients with metastatic breast cancer previously treated with anthracycline: Randomized phase II multicenter trial
Sung-Bae Kim, Changhoon Yoo, Jungsil Ro, Seock-Ah Im, Young-Hyuck Im, Jee Hyun Kim, Jin-Hee Ahn, Kyung Hae Jung, Hong Suk Song, Seok Yun Kang, Hee Sook Park, Hyun-Cheol Chung
A phase I/II trial of capecitabine combined with peginterferon α-2a in Patients with sorafenib-refractory advanced hepatocellular carcinoma
Sadahisa Ogasawara, Tetsuhiro Chiba, Yoshihiko Ooka, Naoya Kanogawa, Tenyu Motoyama, Eiichiro Suzuki, Akinobu Tawada, Fumihiko Kanai, and Osamu Yokosuka
Kidney injuries related to ipilimumab
Hassane Izzedine, Victor Gueutin, Chems Gharbi, Christine Mateus, Caroline Robert, Emilie Routier, Marina Thomas, Alain Baumelou, Philippe Rouvier
Dysphonia induced by anti-angiogenic compounds
Erika Saavedra, Antoine Hollebecque, Jean-Charles Soria, Dana M. Hartl